IBRX financials
ImmunityBio (IBRX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
IBRX income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $113.29M | $112.53M | -$256.03M | -$351.40M | -0.38 |
| 2024 | $14.74M | $14.74M | -$344.18M | -$413.56M | -0.62 |
| 2023 | $622.00K | $622.00K | -$362.25M | -$583.20M | -1.15 |
| 2022 | $240.00K | $240.00K | -$351.30M | -$416.57M | -1.04 |
| 2021 | $934.00K | $934.00K | -$330.28M | -$346.79M | -0.89 |
| 2020 | $605.00K | $605.00K | -$220.88M | -$221.85M | -0.59 |
- IBRX revenue was $113.29M in fiscal 2025, net income -$351.40M.
Updated 2026-11-07 11:55 UTC